Privia Health Group, Inc. (NASDAQ:PRVA) CFO Sells $42,734.40 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 2,320 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $42,734.40. Following the completion of the transaction, the chief financial officer now owns 259,959 shares in the company, valued at $4,788,444.78. The transaction was disclosed in a filing with the SEC, which is available at this link.

David Mountcastle also recently made the following trade(s):

• On Tuesday, April 2nd, David Mountcastle sold 3,933 shares of Privia Health Group stock. The shares were sold at an average price of $17.77, for a total transaction of $69,889.41.

Privia Health Group Trading Up 1.8 %

Shares of Privia Health Group stock opened at $18.74 on Friday. Privia Health Group, Inc. has a twelve month low of $17.54 and a twelve month high of $30.15. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of 98.64, a price-to-earnings-growth ratio of 2.56 and a beta of 0.81. The company has a fifty day moving average price of $19.62 and a 200 day moving average price of $21.12.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). The company had revenue of $440.80 million during the quarter, compared to analysts’ expectations of $425.81 million. Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. Privia Health Group’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.14 EPS. Analysts forecast that Privia Health Group, Inc. will post 0.26 earnings per share for the current year.

Institutional Trading of Privia Health Group

A number of hedge funds have recently made changes to their positions in PRVA. Norges Bank acquired a new stake in Privia Health Group during the 4th quarter valued at $27,959,000. Riverbridge Partners LLC lifted its stake in shares of Privia Health Group by 17.5% in the first quarter. Riverbridge Partners LLC now owns 5,399,662 shares of the company’s stock worth $105,779,000 after acquiring an additional 804,304 shares in the last quarter. Avidity Partners Management LP boosted its holdings in Privia Health Group by 43.1% in the third quarter. Avidity Partners Management LP now owns 1,545,100 shares of the company’s stock valued at $35,537,000 after purchasing an additional 465,294 shares during the last quarter. Northern Trust Corp boosted its holdings in Privia Health Group by 28.7% in the third quarter. Northern Trust Corp now owns 1,344,327 shares of the company’s stock valued at $30,920,000 after purchasing an additional 299,395 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Privia Health Group by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,278,334 shares of the company’s stock worth $259,740,000 after purchasing an additional 274,345 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Wall Street Analysts Forecast Growth

PRVA has been the subject of several recent analyst reports. Stifel Nicolaus lowered their target price on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday. Jefferies Financial Group initiated coverage on Privia Health Group in a research report on Monday, February 26th. They set a “buy” rating and a $25.00 target price on the stock. Citigroup began coverage on Privia Health Group in a report on Monday, April 22nd. They issued a “buy” rating and a $25.00 price target for the company. Barclays began coverage on shares of Privia Health Group in a research note on Wednesday, March 6th. They set an “equal weight” rating and a $22.00 price objective for the company. Finally, Bank of America downgraded shares of Privia Health Group from a “buy” rating to a “neutral” rating and lowered their target price for the company from $27.00 to $21.00 in a report on Thursday, February 22nd. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.62.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.